ACT Secures Approval to Proceed with Increased RPE Dosage for Patients in Clinical Trial for Dry AMD
July 12, 2012
Advanced Cell Technology, Inc. (OTCBB: ACTC) announced earlier this week that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the company’s three ongoing clinical trials, has authorized the company to move forward with enrollment and treatment of additional patients in its clinical trial for dry age-related macular degeneration (dry AMD). ACT will proceed with patient screening and enrollment for the second cohort, who, in keeping with trial protocol, will be injected with 100,000 retinal pigment epithelial (RPE) cells derived from human embryonic stem cells (hESCs), as compared with the 50,000-cell dose used in the first cohort.
The trial is a prospective, open-label study, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD at 12 months.
Click here to read the full press release.
You might also enjoy...
- Can ACTC’s Stem Cells be Used to Treat Severe Myopia?
- Using Stem Cells to Treat Dry AMD and Stargardt’s Macular Dystrophy
- First Patients With Macular Degeneration and Stargardt’s Disease Receive Stem Cell Treatment
- Advanced Cell Technology Obtains FDA Approval to Treat Dry AMD with Embryonic Stem Cells
- ACT Adds Third Clinical Trial Site for Testing Treatment of Dry Macular Degeneration With Embryonic Stem Cells
Jump down to form below to submit your own comments